{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(12)"],"submitter":["Saglimbene V"],"pubmed_abstract":["Background
The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.Methods
In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB monotherapy or combination therapy, targeting BP<130/80 in patients with moderate or severe albuminuria and diabetes or other cardiovascular risk factors. End points included a primary composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for cardiovascular causes and a revised end point of all-cause mortality. Additional end points included ESRD, dou"],"journal":["Journal of the American Society of Nephrology : JASN"],"pagination":["2890-2899"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6287867"],"repository":["biostudies-literature"],"pubmed_title":["The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial."],"pmcid":["PMC6287867"],"pubmed_authors":["Maione A","Morano S","Tonelli M","Palmer SC","Nicolucci A","Procaccini DA","Johnson DW","Lamacchia O","Vecchio M","Pellegrini F","Lucisano G","Hegbrant J","De Cosmo S","Gesualdo L","Palasciano G","Saglimbene V","Tognoni G","Long-Term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) Investigators","Ariano R","Sasso A","Pugliese G","Strippoli GFM","Natale P","Craig JC","Filardi T","Ruospo M"],"additional_accession":[]},"is_claimable":false,"name":"The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.","description":"Background
The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.Methods
In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB monotherapy or combination therapy, targeting BP<130/80 in patients with moderate or severe albuminuria and diabetes or other cardiovascular risk factors. End points included a primary composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for cardiovascular causes and a revised end point of all-cause mortality. Additional end points included ESRD, dou","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Dec","modification":"2026-07-16T17:34:37.707Z","creation":"2025-04-05T20:37:23.468Z"},"accession":"S-EPMC6287867","cross_references":{"pubmed":["30420421"],"doi":["10.1681/asn.2018040443","10.1681/ASN.2018040443"]}}